Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1736660 | 0.89 | NR4A2 (0.49) | NR4A2KMT2AMEN1NR1H4AKR1C3 | |
| SCHEMBL3661541 | 0.86 | PLAU (0.48) | NR4A2KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL29375550 | 0.77 | NR4A2 (0.52) | NR4A2KMT2AMEN1NR1H4AKR1C3 | |
| SCHEMBL11774367 | 0.74 | NPC1 (0.54) | KMT2AMEN1SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL16011563 | 0.73 | NR4A2 (0.66) | NR4A2KMT2AMEN1NR1H4AKR1C3 | |
| SCHEMBL17400975 | 0.73 | NR4A2 (0.61) | NR4A2KMT2AMEN1NR1H4AKR1C3 | |
| SCHEMBL18486571 | 0.71 | AKR1C3 (0.61) | NR4A2KMT2ANR1H4AKR1C3MRGPRX4 | |
| SCHEMBL28845536 | 0.70 | AKR1C3 (0.61) | NR4A2KMT2ANR1H4AKR1C3RAB9A | |
| SCHEMBL24359722 | 0.70 | SRC (0.48) | KMT2AMEN1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL9178371 | 0.70 | AKR1C3 (0.59) | NR4A2KMT2ANR1H4AKR1C3MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150258202-A1 | ANTHOCYANIDIN COMPLEX FOR THE TREATMENT OF MULTIPLE MYELOMA | SAPIOTEC GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-8658686-B2 | Pyrazole compounds having therapeutic effect on multiple myeloma | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-02-25 | — | — | US | disclosed |
| US-20130253204-A1 | PYRAZOLE COMPOUNDS HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-09-26 | — | — | US | disclosed |
| EP-2139482-B1 | TREATMENT FOR MULTIPLE MYELOMA | ARES TRADING SA (CH) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011133654-A1 | ADJUSTABLE WALL SUPPORT SYSTEM AND METHOD | MODERNFOLD, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20100069316-A1 | TREATMENT FOR MULTIPLE MYELOMA | ARES TRADING S.A. | 2010-03-18 | — | — | US | disclosed |
| EP-1635806-B1 | METHOD FOR TREATING ALCOHOLIC HEPATITIS | UNIV PITTSBURGH (US) | 2008-05-28 | — | — | EP | disclosed |
| US-7238489-B2 | Identification of sortase gene | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060223887-A1 | Method for treating acute pancreatitis | UNIVERSITY OF PITTSBURGH- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2006-10-05 | — | — | US | disclosed |
| US-7101692-B2 | Identification of sortase gene | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-09-05 | — | — | US | disclosed |
| US-6773706-B2 | Identification of sortase gene | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-08-10 | — | — | US | disclosed |
| EP-1416955-A2 | IDENTIFICATION OF SORTASE GENE | The Regents of the University of California (US) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003020885-A9 | IDENTIFICATION OF SORTASE GENE | UNIV CALIFORNIA (US) | 2004-04-01 | — | — | WO | disclosed |
| US-20030153020-A1 | Identification of sortase gene | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-08-14 | — | — | US | disclosed |
| US-6565895-B2 | Side-effect reduction of anti-cancer therapy | GELTEX PHARMACEUTICALS, INC. | 2003-05-20 | — | — | US | disclosed |
| WO-2003020885-A2 | IDENTIFICATION OF SORTASE GENE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-03-13 | — | — | WO | disclosed |
| US-20030022178-A1 | Identification of sortase gene | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-30 | — | — | US | disclosed |
| EP-1233780-A1 | IDENTIFICATION OF SORTASE GENE | The Regents of the University of California (US) | 2002-08-28 | — | — | EP | disclosed |
| US-20020081340-A1 | Bismuth compounds for the treatment and prevention of mucositis | GELTEX PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| WO-2000062804-A2 | IDENTIFICATION OF SORTASE GENE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223887-A1 | Method for treating acute pancreatitis | PNLIP, LIPA, AMY2A | NR4A2 4116/4885KMT2A 2730/4885MEN1 4476/4885 |
| US-20100069316-A1 | TREATMENT FOR MULTIPLE MYELOMA | MCL1, BCL6, BCL6B | NR4A2 3578/4885KMT2A 931/4885MEN1 64/4885 |
| US-20150258202-A1 | ANTHOCYANIDIN COMPLEX FOR THE TREATMENT OF MULTIPLE MYELOMA | SDCBP, BCL9, BCL9L | NR4A2 2062/4885KMT2A 2720/4885MEN1 706/4885 |
| US-20130253204-A1 | PYRAZOLE COMPOUNDS HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA | MCL1, BCL6, RTN3 | NR4A2 1997/4885KMT2A 1201/4885MEN1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.